X
(All Fields are required)
Issue Brief

The Superbug Threat
As Drug-resistant bacteria spread, the pipeline for antibiotics is drying up


The Superbug Threat

Humankind is in an arms race with drug-resistant superbugs—and bacteria have the upper hand.

Although drug makers developed 13 new classes of antibiotics between 1935 and 1968, only two new classes of these medications have emerged in the more than four decades since then.1 This leaves doctors with fewer options to fight a rising tide of drug-resistant infections.

If this trend continues, warns Dr. Thomas Frieden, director of the Centers for Disease Control and Prevention, we could enter “a post-antibiotic era.”2

AIP_TheSuperbugThreat.png

Challenges to Antibiotic Innovation

Whereas scientific, economic, and regulatory forces have worked in relative harmony to produce many safe and effective medical treatments, they conspire to slow the development of new antibiotics.

SCIENTIFIC CHALLENGES
Antibiotics are difficult to discover.4

  • The bacteria that present the greatest danger today have sophisticated defense mechanisms that make them difficult to kill with antibiotics—including multiple cell walls, “pumps” to expel some antibiotic molecules, and chemicals that inactivate others.
  • In addition, new drugs must overcome all of these hurdles without poisoning the patient taking them.

ECONOMIC CHALLENGES
Antibiotics tend to produce lower revenues than many other types of drugs.5

  • Antibiotics are used sparingly to slow the rate of resistance.
  • These drugs are often taken for short periods of time (rather than daily for a lifetime like treatments for conditions such as diabetes and hypertension).
  • They tend to be priced lower than other drugs.6

REGULATORY CHALLENGES
Compared with other drug types, it is more difficult to test antibiotics and secure approval for them from the U.S. Food and Drug Administration.7

  • Test subjects for drug trials are hard to find; often, there is a lack of diagnostic tools to identify the particular bacteria causing patients’ infections.
  • The drug approval process for new antibiotics is in flux and needs greater predictability.
Date added:
Mar 1, 2012
Project:
Antibiotics and Innovation Project
Topic:
Antibiotic Innovation
References:
Collapse All
close

References:

1 J. H. Powers, “Antimicrobial Drug Development—the Past, the Present, and the Future,” Clin Microbiol Infect 10 Suppl 4 (2004): 23–31.
2 T. Frieden, “Antibiotic Resistance and the Threat to Public Health,” testimony before the House Committee on Energy and Commerce, Subcommittee on Health, released April 28, 2010.
3 Based on data from: J.H. Powers, “Antimicrobial Drug Development—the Past, the Present, and the Future,” Clin Microbiol Infect 10 Suppl 4 (2004); 23–31.
4 “Innovative Mechanisms for Tackling Antibacterial Resistance,” The Royal Society, last modified July 26, 2008, royalsociety.org/uploadedFiles/Royal_Society_Content/policy/publications/2008/7932.pdf.
5 E. Power, “Impact of Antibiotic Restrictions: The Pharmaceutical Perspective.” Clin Microbiol Infect 12 Suppl 5 (2006): 25–34.
6 T. Parker-Pope, “Free Antibiotics May Contribute to Drug Resistance, Officials Say,” New York Times, March 4, 2009, www.nytimes.com/2009/03/05/health/policy/05drugs.html.
7 D. M. Shlaes, Antibiotics: The Perfect Storm. New York: Springer Science+Business Media, 2010.

Related Resources

FDA Releases Draft Guidance on Antibacterial Drug Development

Other Resource

Nearly a year after the enactment of the Generating Antibiotic Incentives Now Act, the U.S. Food and Drug Administration has released draft guidance for industry on developing antibacterial therapies for patients with unmet medical needs.

More

Drug Development for Limited Populations: A New Proposed Pathway

Issue Brief
The lack of new antibiotics and the rise in drug resistance have rendered some serious and life-threatening infections untreatable, and the health care community is searching for ways to bring innovative new drugs to patients whose treatment options are limited or nonexistent. More

A New Pathway for Antibiotic Innovation: Exploring Drug Development for Limited Populations

Other Resource

As multidrug-resistant infections have grown more prevalent, few new antibiotics are reaching the market. This is attributed, in part, to the economic and regulatory challenges associated with their development. Recently, stakeholders have endorsed a novel regulatory pathway to approve these lifesaving drugs for use in limited patient populations — namely those at highest risk and with few or no other options.

More

''Overused Antibiotics are Becoming Ineffective''

Opinion

"As a nation, we need to exercise greater care with our use of antibiotics, in both humans and animals, so that these medications remain effective in treating serious bacterial infections."

More

National Public Health Week

Other Resource
This year's celebration of National Public Health Week (NPHW) focuses on the theme, "Public Health is ROI: Save Lives, Save Money." Join us in recognizing the work of Pew's Health Initiatives. More